

## AMENDMENT

### In the Claims:

Please cancel claims 1-10 without prejudice or disclaimer to presentation in a later application.

This listing of claims will replace all prior versions and listings of claims in the application.

### Listing of Claims:

**1-10.** (Canceled)


**11.** (Original) A method of inhibiting Factor XIa in a mammal by administration of a small organic compound with an  $IC_{50}$  for inhibiting Factor XIa of less than 120 nM.

**12.** (Original) The method of claim 11, wherein the small organic compound has an  $IC_{50}$  for inhibiting Factor XIa of less than 10 nM.

**13.** (Original) The method of claim 11, wherein the small organic compound has an  $IC_{50}$  for inhibiting Factor XIa of less than 6 nM.

**14.** (Original) The method of claim 11, wherein the small organic compound has an  $IC_{50}$  for inhibiting Factor XIa of less than 1 nM.

**15.** (Original) A method of inhibiting Factor XIa in a mammal by administration of a small organic compound having the formula (I):



wherein:

R<sub>1</sub> and R<sub>2</sub> are hydrogen;

R<sub>3</sub> is hydrogen or CH<sub>3</sub>;

R<sub>4</sub> is selected from hydrogen, CH<sub>3</sub>, -CO<sub>2</sub>R<sub>7</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, phenyl, benzyl, and phenylethyl, wherein R<sub>7</sub> is hydrogen, C<sub>1-6</sub>alkyl, benzyl, or -CH(OCOCH<sub>3</sub>)CH<sub>3</sub>; and each R<sub>4</sub> group is optionally substituted with one to two R<sub>12</sub>;

Y is C(=O) or -SO<sub>2</sub>-; wherein when Y is C(=O), then R<sub>6</sub> is C<sub>1-6</sub>alkyl, aryl, heteroaryl, or -NR<sub>10</sub>R<sub>11</sub>, and when Y is -SO<sub>2</sub>-, then R<sub>6</sub> is aryl or heteroaryl; and each R<sub>6</sub> group is optionally substituted with one to two R<sub>12</sub>;

R<sub>8</sub> and R<sub>9</sub> are individually selected from hydrogen and C<sub>1-6</sub>alkyl, or R<sub>8</sub> and R<sub>9</sub> taken together form a five or six membered heterocyclo ring optionally substituted with one to two R<sub>12</sub> and up to one R<sub>13</sub>;

R<sub>10</sub> and R<sub>11</sub> are individually selected from hydrogen, phenyl, or C<sub>1-6</sub>alkyl optionally substituted with phenyl, or R<sub>10</sub> and R<sub>11</sub> taken together form a five or six membered heterocyclo ring optionally substituted with one to two R<sub>12</sub> and up to one R<sub>13</sub>;


R<sub>12</sub> is selected from hydrogen, halogen, trifluoromethyl, trifluoromethoxy, lower alkyl, amino, lower alkylamino, -CO<sub>2</sub>H, -CO<sub>2</sub>(lower alkyl), or a five or six membered saturated or unsaturated heterocyclo having up to two nitrogen heteroatoms;

R<sub>13</sub> is selected from -C(=O)(C<sub>1-6</sub>alkyl), -CO<sub>2</sub>(C<sub>1-6</sub>alkyl), -C(=O)NH(C<sub>1-6</sub>alkyl), and five or six membered heterocyclo optionally substituted with one to two R<sub>14</sub>; and

$R_{14}$  is selected from hydrogen, phenyl, or  $C_{1-6}$ alkyl optionally substituted with phenyl;


or a prodrug carbamate thereof wherein at least one of  $R_1$  and  $R_2$  is COOR, wherein R is hydrogen,  $C_{1-6}$ alkyl, benzyl, or  $CH(OCOCH_3)CH_3$ , or a pharmaceutically-acceptable salt or hydrate of said compound or prodrug carbamate.

16. (Original) The method of claim 15, wherein the small organic compound has the formula (Ia):




wherein:


$R_3$  is hydrogen or  $CH_3$ ;



Y is  $C(=O)$  or  $-SO_2-$ ; wherein:


when Y is  $C(=O)$ , then  $R_6$  is methyl, ethyl propyl,






$\text{R}_{12}$  is selected from hydrogen, lower alkyl, amino, lower alkylamino,  $-\text{CO}_2\text{H}$ , and  $-\text{CO}_2$ (lower alkyl); or a prodrug carbamate thereof wherein at least one of  $\text{R}_1$  and  $\text{R}_2$  is  $-\text{COOR}$ , wherein R is hydrogen,  $\text{C}_{1-6}$ alkyl, benzyl, or  $-\text{CH}(\text{OCOCH}_3)\text{CH}_3$ , or a pharmaceutically-acceptable salt or hydrate of said compound or prodrug carbamate; wherein the compound has an  $\text{IC}_{50}$  for inhibiting Factor XIa of less than 20 nM.

17. (Original) The method of claim 15, wherein the small organic compound has the formula (Ib),



wherein:

$\text{R}_6$  is selected from:



or a prodrug carbamate thereof wherein at least one of  $\text{R}_1$  and  $\text{R}_2$  is  $-\text{COOR}$ , wherein  $\text{R}_{12}$  is defined as above; R is hydrogen,  $\text{C}_{1-6}$ alkyl, benzyl, or  $-\text{CH}(\text{OCOCH}_3)\text{CH}_3$ , or a

pharmaceutically-acceptable salt or hydrate of said compound or prodrug carbamate; wherein the compound has an  $IC_{50}$  for inhibiting Factor XIa of less than 3 nM.